Evaluation of Immune Suppression in Multiple Myeloma Patients
Treated with Lenalidomide Plus Prednisone and Lenalidomide
Alone.

a 2012

Evaluation of Immune Suppression in Multiple Myeloma Patients Treated with Lenalidomide Plus Prednisone and Lenalidomide Alone.

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ and Roman HÁJEK

Basic information

Original name

Evaluation of Immune Suppression in Multiple Myeloma Patients Treated with Lenalidomide Plus Prednisone and Lenalidomide Alone.

Authors

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ and Roman HÁJEK

Edition

54th ASH Annual Meeting and Exposition, Atlanta, USA, 2012

Other information

Language

English

Type of outcome

Conference abstract

Field of Study

30200 3.2 Clinical medicine

Country of publisher

United States of America

Confidentiality degree

is not subject to a state or trade secret

Organization unit

Faculty of Medicine

Keywords in English

Multiple myeloma; lenalidomide; prednisone

Abstract

In the original language

Lenalidomide is one of the immunomodulatory drugs (IMiDs), which function efficiently as immune system modulator and interfere with tumor and its microenvironment via anti-angiogenic, anti-proliferative and anti-inflammatory effects, and also down regulate adhesion molecules in tumor cells. Lenalidomide has significantly improved survival outcome in multiple myeloma (MM) patients. Recently, we and others have shown that lenalidomide in combination with dexamethasone increased the immune suppressor cell numbers in MM patients (Muthu Raja et al, 2012; Minnema et al, 2009). Also, an in vivo study showed that anti-tumor properties of lenalidomide are not compromised by dexamethasone but lenalidomide induced immune modulatory effects are reduced. Here in this study, we aimed to compare the immune suppressor cells and other immune cells in multiple myeloma patients who are treated with lenalidomide plus prednisone (LP) and lenalidomide alone (L). Conclusions: Our study clearly showed that immune suppressor cells including, Tregs and MDSCs were significantly increased in MM patients treated with lenalidomide plus prednisone compared to patients treated with lenalidomide alone. Increase in immune suppressor cells might be due to inclusion of prednisone with lenalidomide. This finding is also further supported by lenalidomide arm data, where no significant increase in immune suppressor cells was observed. Expanded immune suppressor cells in lenalidomide plus prednisone treated cohort might be more susceptible to infectious complications and progression risk.

Links

GAP304/10/1395, research and development project

Name: Analýza klonálních progenitorů plazmatických buněk u monoklonálních gamapatií

Investor: Czech Science Foundation

MSM0021622434, plan (intention)

Name: Od klasických prognostických markerů ke klinicky aplikovatelným farmakogenomickým a farmakoproteomickým projektům u mnohočetného myelomu a monoklonálních gamapatií

Investor: Ministry of Education, Youth and Sports of the CR, From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies

Cite

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ and Roman HÁJEK. Evaluation of Immune Suppression in Multiple Myeloma Patients Treated with Lenalidomide Plus Prednisone and Lenalidomide Alone. In 54th ASH Annual Meeting and Exposition, Atlanta, USA. 2012.

@proceedings{1080496,
   author = {Muthu Raja, Karthick Raja and Říhová, Lucie and Hájek, Roman},
   booktitle = {54th ASH Annual Meeting and Exposition, Atlanta, USA},
   keywords = {Multiple myeloma; lenalidomide; prednisone},
   language = {eng},
   title = {Evaluation of Immune Suppression in Multiple Myeloma Patients Treated with Lenalidomide Plus Prednisone and Lenalidomide Alone.},
   year = {2012}
}

TY  - CONF
ID  - 1080496
AU  - Muthu Raja, Karthick Raja - Říhová, Lucie - Hájek, Roman
PY  - 2012
TI  - Evaluation of Immune Suppression in Multiple Myeloma Patients Treated with Lenalidomide Plus Prednisone and Lenalidomide Alone.
KW  - Multiple myeloma
KW  - lenalidomide
KW  - prednisone
N2  - Lenalidomide is one of the immunomodulatory drugs (IMiDs), which function efficiently as immune system modulator and interfere with tumor and its microenvironment via anti-angiogenic, anti-proliferative and anti-inflammatory effects, and also down regulate adhesion molecules in tumor cells. Lenalidomide has significantly improved survival outcome in multiple myeloma (MM) patients. Recently, we and others have shown that lenalidomide in combination with dexamethasone increased the immune suppressor cell numbers in MM patients (Muthu Raja et al, 2012; Minnema et al, 2009). Also, an in vivo study showed that anti-tumor properties of lenalidomide are not compromised by dexamethasone but lenalidomide induced immune modulatory effects are reduced. Here in this study, we aimed to compare the immune suppressor cells and other immune cells in multiple myeloma patients who are treated with lenalidomide plus prednisone (LP) and lenalidomide alone (L). Conclusions: Our study clearly showed that immune suppressor cells including, Tregs and MDSCs were significantly increased in MM patients treated with lenalidomide plus prednisone compared to patients treated with lenalidomide alone. Increase in immune suppressor cells might be due to inclusion of prednisone with lenalidomide. This finding is also further supported by lenalidomide arm data, where no significant increase in immune suppressor cells was observed. Expanded immune suppressor cells in lenalidomide plus prednisone treated cohort might be more susceptible to infectious complications and progression risk.
ER  -

MUTHU RAJA, Karthick Raja; Lucie ŘÍHOVÁ and Roman HÁJEK. Evaluation of Immune Suppression in Multiple Myeloma Patients Treated with Lenalidomide Plus Prednisone and Lenalidomide Alone. In \textit{54th ASH Annual Meeting and Exposition, Atlanta, USA}. 2012.

Přehled o publikaci